Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares traded down 5.6% during mid-day trading on Wednesday . The company traded as low as $91.12 and last traded at $94.75. 2,603,979 shares were traded during trading, an increase of 182% from the average session volume of 923,125 shares. The stock had previously closed at $100.35.
A number of research analysts recently issued reports on the stock. ValuEngine downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 21st. BidaskClub upgraded shares of Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, July 21st. Stifel Nicolaus upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the company from $95.00 to $125.00 in a research report on Monday, August 6th. Piper Jaffray Companies decreased their target price on shares of Alnylam Pharmaceuticals from $182.00 to $160.00 and set an “overweight” rating for the company in a research report on Wednesday, June 27th. Finally, Needham & Company LLC restated a “buy” rating and set a $152.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, August 13th. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $141.57.
The company has a current ratio of 13.22, a quick ratio of 13.22 and a debt-to-equity ratio of 0.02. The firm has a market cap of $10.97 billion, a price-to-earnings ratio of -17.48 and a beta of 2.57.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.11. Alnylam Pharmaceuticals had a negative net margin of 533.52% and a negative return on equity of 38.09%. The company had revenue of $29.91 million during the quarter, compared to analysts’ expectations of $16.96 million. During the same quarter in the previous year, the company earned ($1.07) earnings per share. The firm’s revenue for the quarter was up 87.8% on a year-over-year basis. analysts predict that Alnylam Pharmaceuticals, Inc. will post -7.27 earnings per share for the current fiscal year.
In other news, COO Yvonne Greenstreet sold 2,500 shares of the business’s stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $120.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief operating officer now owns 1,916 shares of the company’s stock, valued at $229,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Laurie Keating sold 1,563 shares of the business’s stock in a transaction dated Wednesday, June 20th. The stock was sold at an average price of $105.04, for a total transaction of $164,177.52. Following the sale, the senior vice president now directly owns 16,063 shares of the company’s stock, valued at approximately $1,687,257.52. The disclosure for this sale can be found here. Insiders sold 54,063 shares of company stock valued at $5,733,678 in the last ninety days. 3.70% of the stock is owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in ALNY. State Board of Administration of Florida Retirement System increased its stake in shares of Alnylam Pharmaceuticals by 1.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 117,826 shares of the biopharmaceutical company’s stock worth $14,033,000 after purchasing an additional 1,606 shares in the last quarter. Robeco Institutional Asset Management B.V. purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth about $170,000. Schwab Charles Investment Management Inc. increased its stake in shares of Alnylam Pharmaceuticals by 5.7% during the first quarter. Schwab Charles Investment Management Inc. now owns 277,352 shares of the biopharmaceutical company’s stock worth $33,033,000 after purchasing an additional 14,936 shares in the last quarter. American International Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 44.8% during the first quarter. American International Group Inc. now owns 2,906 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 899 shares in the last quarter. Finally, Aperio Group LLC increased its stake in shares of Alnylam Pharmaceuticals by 12.9% during the first quarter. Aperio Group LLC now owns 23,797 shares of the biopharmaceutical company’s stock worth $2,834,000 after purchasing an additional 2,719 shares in the last quarter. 93.36% of the stock is owned by institutional investors and hedge funds.
Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Featured Article: What are CEFs?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.